Profluent

Visit Website

AI-first protein design company from ex-Salesforce Research leader Ali Madani and UW microbiologist Alexander Meeske; created OpenCRISPR-1, the world's first fully AI-designed gene editor, and partners with Eli Lilly on protein design.

Headquarters

Berkeley, USA

Year Founded

2022

Founders

Ali Madani, Alexander Meeske

Country

United States

Financial Information

Funding Stage

Series A

Recent Funding

$35M

Funding By

Spark Capital, Air Street Capital, Insight Partners

Core Technology

Generative protein language models + OpenCRISPR gene editors

Product Type

Drug + AI Platform

Pipeline Stage (Very Important)

Discovery / Platform

Regulatory Status

IND Filed: No
FDA/EMA Status: N/A
Clinical Trial Registration: N/A
Patents / IP Status: Filed; OpenCRISPR-1 open-sourced for research

Partnerships

Pharma Collaborations

Eli Lilly

Academic / Hospital Tie-ups

University of Washington

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

First AI-designed CRISPR gene editor, open-sourced; validated by Eli Lilly deal